Study S000679

Research of Exenatide for Management of Reproductive and Metabolic Dysfunction in Overweight/Obese PCOS Patients With Impaired Glucose Regulation

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT03352869
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: NONE
Status: COMPLETED
Enrollment: 183
Start: 2017-11-28
Primary completion: 2018-07-01
Lead sponsor: RenJi Hospital
Conditions: Polycystic Ovary Syndrome; Overweight and Obesity; Disorder of Glucose Regulation
Interventions: DRUG:Exenatide; DRUG:Metformin
Results posted: FALSE
Individual participant data sharing: UNDECIDED

Registered primary outcomes

Improvement of intravenous blood glucose from impaired glucose regulation to normal glucose regulation [up to 12 weeks]

Linked records (7)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0025681	Exenatide, Metformin, or Both for Prediabetes in PCOS: A Randomized, Open-label, Parallel-group Controlled Study. Tao T, The Journal of clinical endocrinology and metabolism	2021	Randomized trial	PMID 32995892 DOI	cites ClinicalTrials.gov:NCT03352869; registry reference DERIVED:32995892
R0022935	Short-term effectiveness of low dose liraglutide in combination with metformin versus high dose liraglutide alone in treatment of obese PCOS: randomized trial. Jensterle M, BMC endocrine disorders	2017	Randomized trial	PMID 28143456 DOI	registry reference RESULT:28143456
R0013774	Short-term intervention with liraglutide improved eating behavior in obese women with polycystic ovary syndrome. Jensterle M, Endocrine research	2015	Other trial	PMID 25330463 DOI	registry reference BACKGROUND:25330463
R0026909	The effects of treatment with liraglutide on atherothrombotic risk in obese young women with polycystic ovary syndrome and controls. Kahal H, BMC endocrine disorders	2015	Other trial	PMID 25880805 DOI	registry reference BACKGROUND:25880805
R0018103	Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin. Jensterle Sever M, European journal of endocrinology	2014	Randomized trial	PMID 24362411 DOI	registry reference BACKGROUND:24362411
R0022672	Glucagon-like peptide-1 analogue, liraglutide, improves liver fibrosis markers in obese women with polycystic ovary syndrome and nonalcoholic fatty liver disease. Kahal H, Clinical endocrinology	2014	Nonrandomized study	PMID 24256515 DOI	registry reference BACKGROUND:24256515
R0028017	Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome. Elkind-Hirsch K, The Journal of clinical endocrinology and metabolism	2008	Randomized trial	PMID 18460557 DOI	registry reference BACKGROUND:18460557